Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd. is listed today as Kiniksa Pharmaceuticals, Ltd.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2019 | $9 M | Private placement after listing | $2 to $10 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Kiniksa Pharmaceuticals, Ltd., its revenue in fiscal 2024 came from these product and service lines: License and collaboration revenue $6.21 million (1%).
Annual report (SEC XBRL) · Dec 2024
Kiniksa Pharmaceuticals, Ltd. chose not to state its revenue in its newest notice of a funding round (Nov 2020).
SEC Form D · Nov 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2020
Products and services#
No products or services of Kiniksa Pharmaceuticals, Ltd. are on record.
Investors#
15 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 667, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2018) | SEC Form 3 |
| Baker Bros. Advisors (GP) LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2018) | SEC Form 3 |
| Baker Bros. Advisors LP | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2018) | SEC Form 3 |
| Baker Brothers Life Sciences LP | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2018) | SEC Form 3 |
| Carsten Boess | Person | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Chris Heberlig | Person | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Cormorant Private Healthcare Fund I, LP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Sanj K. Patel | Person | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2018) | SEC Form 3 |
| Stephen F. Mahoney | Person | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Thomas W. Beetham | Person | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
Largest shareholders today
Institutions holding Kiniksa Pharmaceuticals, Ltd. shares, as of Sep 30, 2026.
- FMR LLC$559 M9.18%
- BlackRock, Inc.$220 M3.61%
- Baker Bros. Advisors LP$211 M3.48%
- Rubric Capital Management LP$210 M3.45%
- Tang Capital Management LLC$169 M2.77%
- Vanguard Portfolio Management LLC$152 M2.49%
- Vanguard Capital Management LLC$107 M1.76%
- Arrowstreet Capital, Limited Partnership$82 M1.34%
- Morgan Stanley$70 M1.15%
- State Street Corp$69 M1.14%
- Spruce Street Capital LP$68 M1.13%
- Pictet Asset Management Holding SA$64 M1.05%
- Invesco Ltd.$63 M1.04%
- Dimensional Fund Advisors LP$63 M1.03%
- Driehaus Capital Management LLC$53 M0.86%
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Sanj K Patel | Executive officer | Nov 2020 |
| Thomas W Beetham | Executive officer | Nov 2020 |
| Chris K Heberlig | Executive officer | Jul 2019 |
| Barry D Quart | Director | Nov 2020 |
| Felix J Baker | Director | Nov 2020 |
| G. Bradly D Cole | Director | Nov 2020 |
| Kimberly J Popovits | Director | Nov 2020 |
| Richard S Levy | Director | Nov 2020 |
| Sanj K Patel | Director | Nov 2020 |
| Stephen R Biggar | Director | Nov 2020 |
| Thomas R Malley | Director | Nov 2020 |
| Tracey L Mccain | Director | Nov 2020 |
Went public since 2018. Its SEC number is that of a company listed on a stock exchange.